[1. J. K. Liao and U. Laufs, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118; DOI: 10.1146/annurev.pharmtox.45.120403.095748.10.1146/annurev.pharmtox.45.120403.095748269458015822172]Search in Google Scholar
[2. S. Wolfrum, K. S. Jensen and J. K. Liao, Endothelium-dependent effects of statins, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736; DOI: 10.1161/01.ATV.0000063385.12476.A7.10.1161/01.ATV.0000063385.12476.A712615672]Search in Google Scholar
[3. L. Taraseviciene-Stewart, R. Scerbavicius, K. H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper and N. F. Voelkel, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension, Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006) L668-L676; DOI: 10.1152/ ajplung.00491.2005.]Search in Google Scholar
[4. R. E. Girgis, D. Li, X. Zhan, J. G. Garcia, R. M. Tuder, P. M. Hassoun and R. A. Johns, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin, Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H938-945; DOI: 10.1152/ajpheart.01097.2002.10.1152/ajpheart.01097.200212750068]Search in Google Scholar
[5. F. Simko, Statins: a perspective for left ventricular hypertrophy treatment, Eur. J. Clin. Invest. 37 (2007) 681-691; DOI: 10.1111/j.1365-2362.2007.01837.x.10.1111/j.1365-2362.2007.01837.x17696957]Search in Google Scholar
[6. P. J. Delahoy, D. J. Magliano, K. Webb, M. Grobler and D. Liew, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis, Clin. Ther. 31 (2009) 236-244; DOI: 10.1016/j.clinthera.2009.02.017.10.1016/j.clinthera.2009.02.01719302897]Search in Google Scholar
[7. M. Satoh and A. Satoh, 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension, J. Pharm. Pharm. Sci. 11 (2009) 118s-130s.]Search in Google Scholar
[8. X. Sun and D. D. Ku, Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H801-H809; DOI: 10.1152/ajpheart.01112.2007.10.1152/ajpheart.01112.200718055512]Search in Google Scholar
[9. Y. Pei, P. Ma, X. Wang, W. Zhang, X. Zhang, P. Zheng, L. Yan, Q. Xu and G. Dai, Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism, Eur. J. Pharmacol. 666 (2011) 165-172; DOI: 10.1016/j. ejphar.2011.05.035.]Search in Google Scholar
[10. V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario and K. C. Dellsperger, Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1128-1139; DOI: 10.1152/ajpheart.00048.2009.10.1152/ajpheart.00048.2009275597619633211]Search in Google Scholar
[11. T. Kuang, J. Wang, B. Pang, X. Huang, E. D. Burg, J. X. Yuan and C. Wang, Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats, Pulm. Pharmacol. Ther. 23 (2010) 456-464; DOI: 10.1016/j.pupt.2010.02.003.10.1016/j.pupt.2010.02.003310805920188205]Search in Google Scholar
[12. L. Zhao, A. Sebkhi, O. Ali, B. Wojciak-Stothard, L. Mamanova, Q. Yang, J. Wharton and M. R. Wilkins, Simvastatin and sildenafil combine to attenuate pulmonary hypertension, Eur. Respir. J. 34 (2009) 948-957; DOI: 10.1183/09031936.00143508.10.1183/09031936.0014350819797670]Search in Google Scholar
[13. D. S. Lee, Y. K. Kim and Y. W. Jung, Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension, Korean Circ. J. 40 (2010) 659-664; DOI: 10.4070/ kcj.2010.40.12.659.10.4070/kcj.2010.40.12.659302534021267389]Search in Google Scholar
[14. X. L. Li, R. J. Guan, Q. H. Xu and Z. Y. Wu, [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats], Zhonghua Xin Xue Guan Bing Za Zhi. 39 (2011) 247-253.]Search in Google Scholar
[15. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger and F. Grimminger, Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension, Circ. Res. 94 (2004) 1101-1108; DOI: 10.1161/01.RES.0000126050.41296.8E.10.1161/01.RES.0000126050.41296.8E15031263]Search in Google Scholar
[16. M. Jasińska-Stroschein, J. Owczarek, A. Łuczak, and D. Orszulak-Michalak, The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: A hemodynamic and biochemical study, Pharmacology 91 (2013) 178-184; DOI: 10.1159/000346921.10.1159/00034692123428587]Search in Google Scholar
[17. N. Galiè, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger and G. Simonneau, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur. Heart. J. 30 (2009) 2493-2537; DOI: 10.1093/eurheartj/ehp297. 10.1093/eurheartj/ehp29719713419]Search in Google Scholar
[18. M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin and J. S. Gibbs, Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group, Simvastatin as a treatment for pulmonary hypertension trial, Am. J. Respir. Crit. Care Med. 181 (2010) 1106-1113; DOI: 10.1164/rccm.2009111-699OC.10.1164/rccm.2009111-699OC]Search in Google Scholar
[19. C. Transon, T. Leemann and P. Dayer, In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors, Eur. J. Clin Pharmacol. 50 (1996) 209-215.10.1007/s0022800500948737761]Search in Google Scholar
[20. W. J. Zeng, C. M. Xiong, L. Zhao, G. L. Shan, Z. H. Liu, F. Xue Q. Gu, X. H. Ni, Z. H. Zhao, X. S. Cheng, M. R. Wilkins and J. G. He, Atorvastatin in pulmonary arterial hypertension (APATH) study, Eur. Respir. J. 40 (2012) 67-74; DOI: 10.1183/09031936.00149011.10.1183/09031936.0014901122362846]Search in Google Scholar
[21. E. Abulhul, K. McDonald, R. Martos, D. Phelan, J. P. Spiers, M. Hennessy, J. Baugh, C. Watson, C. O’Loughlin and M. Ledwidge, Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide, Clin. Ther. 34 (2012) 91-100; DOI: 10.1016/j.clinthera.2011.11.002.10.1016/j.clinthera.2011.11.00222154198]Search in Google Scholar
[22. Y. Teshima, K. Yufu, H. Akioka, T. Iwao, F. Anan, M. Nakagawa, H. Yonemochi, N. Takahashi, M. Hara and T. Saikawa, Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction, J. Cardiol. 53 (2009) 58-64; DOI: 10.1016/j.jjcc.2008.08.008.10.1016/j.jjcc.2008.08.00819167639]Search in Google Scholar
[23. D. Chen, D. Zhou, J. Qian, F. Chen, L. Guan, L. Dong and J. Ge, Atorvastatin prevents dehydromonocrotaline- induced pulmonary hypertension in beagles, Exp Lung Res. 38 (2012) 333-343; DOI: 10.3109/01902148.2012.702852.10.3109/01902148.2012.70285222888849]Search in Google Scholar
[24. S. Yigitaslan and B. Sirmagul, Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension, Clin. Exp. Hypertens. 34 (2012) 222-229; DOI: 10.3109/10641963.2011.631652.10.3109/10641963.2011.63165222468718]Search in Google Scholar
[25. K. T. Mouchaers, I. Schalij, M. A. de Boer, P. E. Postmus, V. W. van Hinsbergh, G. P. van Nieuw Amerongen, A. Vonk Noordegraaf and W. J. van der Laarse, Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil, Eur. Respir. J. 36 (2010) 800-807; DOI: 10.1183/09031936.00130209. 10.1183/09031936.0013020920351034]Search in Google Scholar